Skip to main content
. Author manuscript; available in PMC: 2014 Oct 1.
Published in final edited form as: J Immunother. 2013 Oct;36(8):10.1097/CJI.0b013e3182a80213. doi: 10.1097/CJI.0b013e3182a80213

Figure 6. As an adjuvant to ACT in immunodeficient hosts, ARI-4175 inhibits M3-9-M tumors and increases survival.

Figure 6

(A) Female Rag1-/- mice were challenged intramuscularly with M3-9-M (1×105) on day 0. Purified splenic T cells (8×106) from M3-9-M primed or naïve C57BL/6 mice were adoptively transferred to Rag1-/- mice by i.v. tail injections one day after tumor challenge. Mice were treated with 100 μg ARI-4175 or saline for 5 weeks starting on day 3. (B) Individual tumor curves demonstrating regression of tumors only with ARI-4175 plus primed T cells. (C) Mice given primed T cells seemed to exhibit slower tumor growth compared to controls, however only mice that received both primed T cells and ARI-4175 exhibited a clear decrease in tumor volume. (D) Mice given ARI-4175 and primed T cells had significantly improved survival compared to all other treatment groups. **p<0.01, ***p<0.001. Data representative of 2 independent experiments.